Literature DB >> 1575455

Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.

G V Sawle1, P M Bloomfield, A Björklund, D J Brooks, P Brundin, K L Leenders, O Lindvall, C D Marsden, S Rehncrona, H Widner.   

Abstract

Two patients with Parkinson's disease who underwent implantation of fetal mesencephalic tissue into the putamen were serially studied using positron emission tomography and [18F]6-L-fluorodopa ([18F]dopa). The uptake of [18F]dopa is related to the functional integrity of the presynaptic dopaminergic system. Preoperative studies revealed a marked decrease in putamen [18F]dopa uptake, with lesser involvement of the caudate. Two and 4 months, respectively, after operation, both patients demonstrated functional improvement, as described elsewhere. One patient was scanned 5, 8, and 13 months after the operation and the other was scanned 7 and 12 months after the operation. In both patients, [18F]dopa uptake increased within the operated putamen despite a progressive decrease in tracer uptake in the unoperated striatal structures. We believe that this increased uptake of [18F]dopa at the implantation site represents functional integrity within a surviving neural graft. While there has been little further clinical improvement beyond the fifth postoperative month, the uptake of [18F]dopa at the operation site in both patients has progressively increased. The kinetic data provide evidence of disease progression in the unoperated striatum, which, balanced against increasing graft function, may explain why clinical improvement reached a plateau within months after surgery.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575455     DOI: 10.1002/ana.410310207

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

Review 2.  Gene transfer approaches to the lysosomal storage disorders.

Authors:  J A Barranger; E O Rice; W P Swaney
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 3.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

4.  Establishment and characterization of immortalized clonal cell lines from fetal rat mesencephalic tissue.

Authors:  K N Prasad; E Carvalho; S Kentroti; J Edwards-Prasad; C Freed; A Vernadakis
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-09       Impact factor: 2.416

Review 5.  Do brain tissue transplants alter personal identity? Inadequacies of some "standard" arguments.

Authors:  G Northoff
Journal:  J Med Ethics       Date:  1996-06       Impact factor: 2.903

6.  Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data.

Authors:  C D Earl; T Reum; J X Xie; J Sautter; A Kupsch; W H Oertel; R Morgenstern
Journal:  Exp Brain Res       Date:  1996-04       Impact factor: 1.972

Review 7.  GPCRs in stem cell function.

Authors:  Van A Doze; Dianne M Perez
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 8.  Induced pluripotent stem cells and neurodegenerative diseases.

Authors:  Chao Chen; Shi-Fu Xiao
Journal:  Neurosci Bull       Date:  2011-04       Impact factor: 5.203

Review 9.  Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

Authors:  Fábio G Teixeira; Miguel M Carvalho; Nuno Sousa; António J Salgado
Journal:  Cell Mol Life Sci       Date:  2013-03-01       Impact factor: 9.261

Review 10.  Cell transplantation for Parkinson's disease: present status.

Authors:  René Drucker-Colín; Leticia Verdugo-Díaz
Journal:  Cell Mol Neurobiol       Date:  2004-06       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.